tyrosinase 368-376 (370D) peptide

**Tyrosinase 368-376 (370D) peptide** is a synthetic peptide antigen derived from the human tyrosinase protein, specifically containing amino acids 368–376 with an aspartic acid (D) substitution at position 370 (sequence YMDGTMSQV). This modification matches a post-translationally edited epitope found naturally on melanoma cells in HLA-A*0201-positive individuals. The peptide is used as a component in cancer immunotherapy strategies, chiefly as a vaccine antigen to induce or augment CD8+ T cell responses against melanoma. The mechanism of action is the stimulation of a cell-mediated immune response targeting melanoma cells that express tyrosinase. The peptide is not used as a branded or approved therapeutic drug but is investigated as a research reagent or in clinical trial immunotherapies for melanoma, often with adjuvants such as incomplete Freund’s adjuvant, QS-21, or GM-CSF to boost immunogenicity[1][2][4]. It is not a stand-alone pharmaceutical product but rather a peptide vaccine candidate/prototype.

Other names

tyrosinase 370D peptidetyrosinase370D peptidetyrosinase-370D peptideYMDGTMSQV